Mirum Pharmaceuticals: A Deep Dive into Recent Performance and Future Prospects
Mirum Pharmaceuticals (NASDAQ: MIRM) has experienced a dynamic period, marked by both stock price fluctuations and significant advancements in its rare disease portfolio. Investors are closely watching the company’s trajectory, weighing recent performance against its long-term growth potential. This article provides a comprehensive overview of Mirum’s current standing, recent developments, and future outlook.
Recent Stock Performance: A Mixed Bag
Mirum’s share price has shown volatility in recent months. As of March 1, 2026, the stock trades at $92.29. While the stock has seen a 18.2% gain year-to-date, recent returns have been more mixed, with a 12.2% decline over the past week and an 8.5% decline over the past 30 days. However, longer-term returns remain strong, with a 94.0% return over the past year and a substantial 286.8% return over three years.
Expanding Rare Disease Portfolio Through Strategic Acquisitions and Approvals
A key driver of investor interest is Mirum’s strategic expansion of its rare disease portfolio. In February 2026, Mirum completed the acquisition of Bluejay Therapeutics, gaining worldwide rights to brelovitug, a promising treatment for hepatitis delta virus. Mirum Pharmaceuticals is positioning itself as a leader in addressing overlooked conditions.
Beyond the Bluejay acquisition, Mirum has similarly secured modern regulatory approvals, including etexlate for cerebrotendinous xanthomatosis (CTX) and a tablet formulation of Livmarli. These advancements broaden the company’s clinical pipeline and product offerings beyond its initial focus on bile-acid programs. Sahm Capital highlights how these approvals deepen Mirum’s commercial reach in specialized niches.
Valuation and Analyst Perspectives
Despite recent stock fluctuations, several analyses suggest Mirum may be undervalued. One narrative points to a fair value of $106.60, based on revenue and margin assumptions. Simply Wall St notes that analysts have a consensus price target of $78.273, with a range from $53.0 to $89.0.
The valuation is driven by expectations of rapid revenue expansion and a move towards profitability. However, the narrative relies heavily on the success of Livmarli and the smooth execution of late-stage clinical trials. Any setbacks in these areas could challenge the positive outlook.
Mirum currently trades on a price-to-sales (P/S) ratio of 10.7x, above its fair ratio of 9.7x, but below the peer average of 12.7x and the wider US biotech average of 12.4x. This discrepancy raises the question of whether it represents a margin of safety or a potential value trap.
Looking Ahead
As brelovitug progresses through clinical milestones and etexlate and the Livmarli tablet formulation gain commercial traction, investors will be closely monitoring the data and adoption trends. Mirum Pharmaceuticals is focused on building a broad pipeline and portfolio devoted to rare diseases, and its recent moves suggest a commitment to long-term growth. PharmaVoice emphasizes this dedication to a diversified rare disease strategy.
Investors are encouraged to conduct their own thorough analysis and consider their individual risk tolerance before making any investment decisions.